14 Jun 2022 | 03:35 pm |
Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.
Under the terms of the agreement, Myovant will receive an upfront payment of US$50 million, and is eligible to receive milestones which could total up to a further US$90.5 million. Myovant will continue to lead the global development of relugolix and provide initial product supply to Accord. Accord will be responsible for certain local clinical development, all commercialization for its territories, and has the option to manufacture relugolix in the future.
The Pinsent Masons transactions team was led by Life Sciences Transactions partner Gina Bicknell, with primary support from solicitor Kiah York and legal director Mario Subramaniam.
Multinational law firm Pinsent Masons has added to it Australian financial services capabilities with the appointment of partner Hannah Griffiths to lead the firm’s restructuring and insolvency practice in Australia.
Multinational law firm Pinsent Masons has advised leading wind turbine repair and maintenance provider GEV Wind Power on the acquisition of the Australian based Rigcom Group.
Multinational law firm Pinsent Masons MPillay has advised Southeast Asian energy company Coro Energy plc on the sale of Coro Europe Limited to Zodiac Energy plc.
Multinational law firm Pinsent Masons has hired transactional life sciences specialist Michael Stewart as partner in its Dublin office as it expands its pan-European Technology, Science and Industry (TSI) capabilities.
Multinational law firm Pinsent Masons has hired Corporate Partner Camille Chiari who joined the firm’s Paris Office.
Multinational law firm Pinsent Masons has hired patent litigation partner James Marshall to join its London office.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on